ADVICOR TABLET (IMMEDIATE RELEASE)

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

NICOTINIC ACID; LOVASTATIN

Pieejams no:

SEPRACOR PHARMACEUTICALS INC

ATĶ kods:

C10BA01

SNN (starptautisko nepatentēto nosaukumu):

LOVASTATIN AND NICOTINIC ACID

Deva:

1000MG; 40MG

Zāļu forma:

TABLET (IMMEDIATE RELEASE)

Kompozīcija:

NICOTINIC ACID 1000MG; LOVASTATIN 40MG

Ievadīšanas:

ORAL

Vienības iepakojumā:

90

Receptes veids:

Prescription

Ārstniecības joma:

HMG-COA REDUCTASE INHIBITORS

Produktu pārskats:

Active ingredient group (AIG) number: 0251302004; AHFS:

Autorizācija statuss:

CANCELLED POST MARKET

Autorizācija datums:

2010-07-26

Produkta apraksts

PRODUCT MONOGRAPH
PR
ADVICOR
®
extended-release niacin and lovastatin tablets
500/20 mg, 750/20 mg, 1000/20 mg and 1000/40 mg Film-Coated Tablets
Lipid Metabolism Regulator
Manufacturer:
DATE OF REVISION
:
Sepracor Pharmaceuticals, Inc.
OCTOBER 29, 2010
Mississauga, Ontario
Canada
CONTROL NO. 141231
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION........................................................ 3
SUMMARY PRODUCT
INFORMATION................................................................................
3
INDICATIONS AND CLINICAL
USE......................................................................................
3
CONTRAINDICATIONS...........................................................................................................
4
WARNINGS AND PRECAUTIONS
.........................................................................................
4
ADVERSE REACTIONS
.........................................................................................................
10
DRUG
INTERACTIONS..........................................................................................................
16
DOSAGE AND
ADMINISTRATION......................................................................................
17
OVERDOSAGE
........................................................................................................................
19
ACTION AND CLINICAL
PHARMACOLOGY....................................................................
19
STORAGE AND STABILITY
.................................................................................................
23
DOSAGE FORMS, COMPOSITION AND
PACKAGING..................................................... 23
PART II: SCIENTIFIC INFORMATION
..............................................................................
24
PHARMACEUTICAL INFORMATION
.................................................................................
24
CLINICAL
TRIALS...........................................................................................